Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma

Maria S. Tretiakova, Sunati Sahoo, Masayuki Takahashi, Muge Turkyilmaz, Nicholas J. Vogelzang, Fan Lin, Thomas Krausz, Bin Tean Teh, Ximing J. Yang

Research output: Contribution to journalArticle

142 Citations (Scopus)

Abstract

Alpha-methylacyl-CoA racemase (AMACR) was first discovered by using cDNA microarray technology as a molecular marker for prostate cancer. Our recent microarray analysis of renal cell carcinomas showed a significant increase of AMACR mRNA levels in papillary renal cell carcinomas, but not in other subtypes. To investigate the value of this marker in pathologic diagnosis, we analyzed AMACR mRNA levels in cDNA microarrays from 70 kidney tumors. Furthermore, we evaluated the AMACR expression in 165 kidney tumors on tissue microarrays and 51 papillary carcinomas of other organs by immunohistochemistry. AMACR mRNA was significantly overexpressed in 7 of 8 papillary renal cell carcinomas with an average of 5.2-fold increase, and only in 2 of 62 nonpapillary kidney tumors. Immunohistochemistry demonstrated strong AMACR positivity in all cases of papillary renal cell carcinomas (41 of 41, 100%), including 6 metastatic papillary renal cell carcinomas, but only focal or weak reactivity in the minority (18 of 124, 15%) of other renal tumors including 13 of 52 clear cell renal cell carcinomas, 3 of 20 oncocytomas, and 2 of 17 urothelial carcinomas. All chromophobe (0 of 18) and sarcomatoid components of renal cell carcinomas (0 of 15) were negative for AMACR. Weak or focal AMACR immunoreactivity was detected in only 4 of 51 (8%) papillary carcinomas arising in other organs (2 of 14 thyroid, 2 of 13 lung, 0 of 6 breast, 0 of 6 endometrium, 0 of 6 ovary, and 0 of 6 pancreas). Using a combination of cDNA microarrays, tissue microarrays, and immunohistochemistry, we identified AMACR as a marker for papillary renal cell carcinoma, which could be valuable in subclassification of renal cell carcinomas and in the differential diagnosis of a metastatic papillary carcinoma.

Original languageEnglish (US)
Pages (from-to)69-76
Number of pages8
JournalAmerican Journal of Surgical Pathology
Volume28
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Renal Cell Carcinoma
Papillary Carcinoma
Oligonucleotide Array Sequence Analysis
Kidney
Immunohistochemistry
Messenger RNA
Neoplasms
Oxyphilic Adenoma
alpha-methylacyl-CoA racemase
Microarray Analysis
Endometrium
Pancreas
Ovary
Prostatic Neoplasms
Thyroid Gland
Breast
Differential Diagnosis
Technology
Carcinoma
Lung

Keywords

  • AMACR
  • P504S
  • Papillary
  • Renal cell carcinoma

ASJC Scopus subject areas

  • Anatomy
  • Pathology and Forensic Medicine

Cite this

Tretiakova, M. S., Sahoo, S., Takahashi, M., Turkyilmaz, M., Vogelzang, N. J., Lin, F., ... Yang, X. J. (2004). Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma. American Journal of Surgical Pathology, 28(1), 69-76. https://doi.org/10.1097/00000478-200401000-00007

Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma. / Tretiakova, Maria S.; Sahoo, Sunati; Takahashi, Masayuki; Turkyilmaz, Muge; Vogelzang, Nicholas J.; Lin, Fan; Krausz, Thomas; Teh, Bin Tean; Yang, Ximing J.

In: American Journal of Surgical Pathology, Vol. 28, No. 1, 01.2004, p. 69-76.

Research output: Contribution to journalArticle

Tretiakova, MS, Sahoo, S, Takahashi, M, Turkyilmaz, M, Vogelzang, NJ, Lin, F, Krausz, T, Teh, BT & Yang, XJ 2004, 'Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma', American Journal of Surgical Pathology, vol. 28, no. 1, pp. 69-76. https://doi.org/10.1097/00000478-200401000-00007
Tretiakova, Maria S. ; Sahoo, Sunati ; Takahashi, Masayuki ; Turkyilmaz, Muge ; Vogelzang, Nicholas J. ; Lin, Fan ; Krausz, Thomas ; Teh, Bin Tean ; Yang, Ximing J. / Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma. In: American Journal of Surgical Pathology. 2004 ; Vol. 28, No. 1. pp. 69-76.
@article{c1884f5829e04442a275c59e9ffdbf3a,
title = "Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma",
abstract = "Alpha-methylacyl-CoA racemase (AMACR) was first discovered by using cDNA microarray technology as a molecular marker for prostate cancer. Our recent microarray analysis of renal cell carcinomas showed a significant increase of AMACR mRNA levels in papillary renal cell carcinomas, but not in other subtypes. To investigate the value of this marker in pathologic diagnosis, we analyzed AMACR mRNA levels in cDNA microarrays from 70 kidney tumors. Furthermore, we evaluated the AMACR expression in 165 kidney tumors on tissue microarrays and 51 papillary carcinomas of other organs by immunohistochemistry. AMACR mRNA was significantly overexpressed in 7 of 8 papillary renal cell carcinomas with an average of 5.2-fold increase, and only in 2 of 62 nonpapillary kidney tumors. Immunohistochemistry demonstrated strong AMACR positivity in all cases of papillary renal cell carcinomas (41 of 41, 100{\%}), including 6 metastatic papillary renal cell carcinomas, but only focal or weak reactivity in the minority (18 of 124, 15{\%}) of other renal tumors including 13 of 52 clear cell renal cell carcinomas, 3 of 20 oncocytomas, and 2 of 17 urothelial carcinomas. All chromophobe (0 of 18) and sarcomatoid components of renal cell carcinomas (0 of 15) were negative for AMACR. Weak or focal AMACR immunoreactivity was detected in only 4 of 51 (8{\%}) papillary carcinomas arising in other organs (2 of 14 thyroid, 2 of 13 lung, 0 of 6 breast, 0 of 6 endometrium, 0 of 6 ovary, and 0 of 6 pancreas). Using a combination of cDNA microarrays, tissue microarrays, and immunohistochemistry, we identified AMACR as a marker for papillary renal cell carcinoma, which could be valuable in subclassification of renal cell carcinomas and in the differential diagnosis of a metastatic papillary carcinoma.",
keywords = "AMACR, P504S, Papillary, Renal cell carcinoma",
author = "Tretiakova, {Maria S.} and Sunati Sahoo and Masayuki Takahashi and Muge Turkyilmaz and Vogelzang, {Nicholas J.} and Fan Lin and Thomas Krausz and Teh, {Bin Tean} and Yang, {Ximing J.}",
year = "2004",
month = "1",
doi = "10.1097/00000478-200401000-00007",
language = "English (US)",
volume = "28",
pages = "69--76",
journal = "American Journal of Surgical Pathology",
issn = "0147-5185",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Expression of Alpha-Methylacyl-CoA Racemase in Papillary Renal Cell Carcinoma

AU - Tretiakova, Maria S.

AU - Sahoo, Sunati

AU - Takahashi, Masayuki

AU - Turkyilmaz, Muge

AU - Vogelzang, Nicholas J.

AU - Lin, Fan

AU - Krausz, Thomas

AU - Teh, Bin Tean

AU - Yang, Ximing J.

PY - 2004/1

Y1 - 2004/1

N2 - Alpha-methylacyl-CoA racemase (AMACR) was first discovered by using cDNA microarray technology as a molecular marker for prostate cancer. Our recent microarray analysis of renal cell carcinomas showed a significant increase of AMACR mRNA levels in papillary renal cell carcinomas, but not in other subtypes. To investigate the value of this marker in pathologic diagnosis, we analyzed AMACR mRNA levels in cDNA microarrays from 70 kidney tumors. Furthermore, we evaluated the AMACR expression in 165 kidney tumors on tissue microarrays and 51 papillary carcinomas of other organs by immunohistochemistry. AMACR mRNA was significantly overexpressed in 7 of 8 papillary renal cell carcinomas with an average of 5.2-fold increase, and only in 2 of 62 nonpapillary kidney tumors. Immunohistochemistry demonstrated strong AMACR positivity in all cases of papillary renal cell carcinomas (41 of 41, 100%), including 6 metastatic papillary renal cell carcinomas, but only focal or weak reactivity in the minority (18 of 124, 15%) of other renal tumors including 13 of 52 clear cell renal cell carcinomas, 3 of 20 oncocytomas, and 2 of 17 urothelial carcinomas. All chromophobe (0 of 18) and sarcomatoid components of renal cell carcinomas (0 of 15) were negative for AMACR. Weak or focal AMACR immunoreactivity was detected in only 4 of 51 (8%) papillary carcinomas arising in other organs (2 of 14 thyroid, 2 of 13 lung, 0 of 6 breast, 0 of 6 endometrium, 0 of 6 ovary, and 0 of 6 pancreas). Using a combination of cDNA microarrays, tissue microarrays, and immunohistochemistry, we identified AMACR as a marker for papillary renal cell carcinoma, which could be valuable in subclassification of renal cell carcinomas and in the differential diagnosis of a metastatic papillary carcinoma.

AB - Alpha-methylacyl-CoA racemase (AMACR) was first discovered by using cDNA microarray technology as a molecular marker for prostate cancer. Our recent microarray analysis of renal cell carcinomas showed a significant increase of AMACR mRNA levels in papillary renal cell carcinomas, but not in other subtypes. To investigate the value of this marker in pathologic diagnosis, we analyzed AMACR mRNA levels in cDNA microarrays from 70 kidney tumors. Furthermore, we evaluated the AMACR expression in 165 kidney tumors on tissue microarrays and 51 papillary carcinomas of other organs by immunohistochemistry. AMACR mRNA was significantly overexpressed in 7 of 8 papillary renal cell carcinomas with an average of 5.2-fold increase, and only in 2 of 62 nonpapillary kidney tumors. Immunohistochemistry demonstrated strong AMACR positivity in all cases of papillary renal cell carcinomas (41 of 41, 100%), including 6 metastatic papillary renal cell carcinomas, but only focal or weak reactivity in the minority (18 of 124, 15%) of other renal tumors including 13 of 52 clear cell renal cell carcinomas, 3 of 20 oncocytomas, and 2 of 17 urothelial carcinomas. All chromophobe (0 of 18) and sarcomatoid components of renal cell carcinomas (0 of 15) were negative for AMACR. Weak or focal AMACR immunoreactivity was detected in only 4 of 51 (8%) papillary carcinomas arising in other organs (2 of 14 thyroid, 2 of 13 lung, 0 of 6 breast, 0 of 6 endometrium, 0 of 6 ovary, and 0 of 6 pancreas). Using a combination of cDNA microarrays, tissue microarrays, and immunohistochemistry, we identified AMACR as a marker for papillary renal cell carcinoma, which could be valuable in subclassification of renal cell carcinomas and in the differential diagnosis of a metastatic papillary carcinoma.

KW - AMACR

KW - P504S

KW - Papillary

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=0346158080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0346158080&partnerID=8YFLogxK

U2 - 10.1097/00000478-200401000-00007

DO - 10.1097/00000478-200401000-00007

M3 - Article

C2 - 14707866

AN - SCOPUS:0346158080

VL - 28

SP - 69

EP - 76

JO - American Journal of Surgical Pathology

JF - American Journal of Surgical Pathology

SN - 0147-5185

IS - 1

ER -